Skip to content
HowShorted

Ernexa Therapeutics Inc. short interest in 2018

In 2018, Ernexa Therapeutics Inc.'s disclosed short interest ran from 0.88% of shares outstanding on 12 Jan 2018 to 1.48% on 31 Dec 2018, a change of +0.60 percentage points. The year's high was 1.48% on 31 Dec 2018 and its low 0.58% on 15 Nov 2018, averaging 0.81% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.60 days on 15 Feb 2018. Full history: Ernexa Therapeutics Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Ernexa Therapeutics Inc. in 2018

2018 in figures

Start of year
0.88% (12 Jan 2018)
End of year
1.48% (31 Dec 2018)
Change
+0.60 pp
High
1.48% (31 Dec 2018)
Low
0.58% (15 Nov 2018)
Average
0.81%
Highest days to cover
16.60 (15 Feb 2018)
SEC filings marked
8

Every report in 2018

Ernexa Therapeutics Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20180.88%6.29
31 Jan 20180.79%2.36
15 Feb 20180.77%16.60
28 Feb 20180.62%6.05
15 Mar 20180.78%1.00results (8-K), 10-K filed
29 Mar 20180.73%1.00
13 Apr 20180.93%1.00
30 Apr 20180.72%2.35
15 May 20180.72%1.00results (8-K), 10-Q filed
31 May 20180.90%2.25
15 Jun 20180.87%3.99
29 Jun 20180.87%7.28
13 Jul 20180.84%10.20
31 Jul 20180.85%3.58
15 Aug 20180.72%2.05results (8-K), 10-Q filed
31 Aug 20180.73%4.52
14 Sep 20180.77%2.90
28 Sep 20180.75%5.24
15 Oct 20180.73%7.36
31 Oct 20180.65%4.51
15 Nov 20180.58%1.34results (8-K), 10-Q filed
30 Nov 20180.67%1.32
14 Dec 20181.05%1.00
31 Dec 20181.48%1.10

See also: Ernexa Therapeutics Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.